Funding for this research was provided by:
Alzheimer's Drug Discovery Foundation (201810-2017419)
Alzheimer Forschung Initiative (20026)
Robert-Koch Institut (1369–341)
Instituto de Salud Carlos III (CP16/00041 and PI19/00144)
Received: 28 September 2021
Accepted: 22 December 2021
First Online: 13 January 2022
: The study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guidelines and was approved by Ethic committees in the University Medical Center, Göttingen, Germany (Reference numbers: 11/11/93, 34/9/07, 6/9/08, 19/11/09) and in the Coimbra University, Coimbra, Portugal (Reference number: HUC-43-09). All study participants or their legal guardians provided written informed consent.
: Not applicable.
: PH, CS, DV, SG, TB, HL, and CB have nothing to disclose. AVP is recipient of a postdoctoral grant of the Beatriu de Pinós program (2018-BP-00129) from the Ministry of Business and Knowledge of the Government of Catalonia, co-funded by the EU Horizon 2020 program under an MSCA grant agreement (801370). MS received funds from the Alzheimer Forschung Initiative (AFI, project no. 20026). IS received an institutional pharma grant (Roche) for a project of investigation on Multiple Sclerosis 2021 and consultations fees for speakers bureau and educational events from Roche, Biogen, and Merck; attended American Academy of Neurology; is supported by Roche; and is Member of the EAN Pannel in dementia Portuguese National Ethics committee. IB is funded by Grupo de Estudos de Envelhecimento Cerebral e Demencia, Sanofi-Genzyme, Fundação Ciência e Tecnologia - FCT, and received honoraria from Merck S.A. JR is funded by the EU grant for blood donation of reconvalescence plasma after COVID19-infection. FL received funding from the ADDF (Alzheimer’s Drug Discovery Foundation, grant 201810-2017419 related to this work) and is recipient of research grants from the Instituto de Salud Carlos III (Institute of Health Carlos III, ISCIII) from the Government of Spain (grants CP16/00041 and PI19/00144). IZ received funding from the ADDF (Alzheimer’s Drug Discovery Foundation, grant 201810-2017419) and the Robert Koch Institute through funds from the German Federal Ministry of Health (grant no. 1369–341).